DE19923551A1 - Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht - Google Patents

Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht

Info

Publication number
DE19923551A1
DE19923551A1 DE19923551A DE19923551A DE19923551A1 DE 19923551 A1 DE19923551 A1 DE 19923551A1 DE 19923551 A DE19923551 A DE 19923551A DE 19923551 A DE19923551 A DE 19923551A DE 19923551 A1 DE19923551 A1 DE 19923551A1
Authority
DE
Germany
Prior art keywords
active ingredient
morphine
diamorphine
transdermal therapeutic
therapeutic system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19923551A
Other languages
German (de)
English (en)
Inventor
Rudolf Matusch
Bernd Adam
Andreas Koch
Hans-Rainer Hoffmann
Bodo Asmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to DE19923551A priority Critical patent/DE19923551A1/de
Priority to RU2001134016/15A priority patent/RU2254130C2/ru
Priority to CA002372339A priority patent/CA2372339C/en
Priority to PCT/EP2000/004458 priority patent/WO2000071125A2/de
Priority to DK00929536T priority patent/DK1183029T3/da
Priority to ES00929536T priority patent/ES2245311T3/es
Priority to JP2001505144A priority patent/JP4892148B2/ja
Priority to CNB008078823A priority patent/CN100457107C/zh
Priority to PL351681A priority patent/PL196741B1/pl
Priority to KR1020017014818A priority patent/KR100742471B1/ko
Priority to EP00929536A priority patent/EP1183029B1/de
Priority to CZ20014187A priority patent/CZ301230B6/cs
Priority to AT00929536T priority patent/ATE300301T1/de
Priority to PT00929536T priority patent/PT1183029E/pt
Priority to BR0011286-0A priority patent/BR0011286A/pt
Priority to NZ515301A priority patent/NZ515301A/xx
Priority to HU0201349A priority patent/HUP0201349A3/hu
Priority to AU47577/00A priority patent/AU772139B2/en
Priority to IL14627700A priority patent/IL146277A0/xx
Priority to TR2001/03302T priority patent/TR200103302T2/xx
Priority to MXPA01011921A priority patent/MXPA01011921A/es
Priority to DE50010833T priority patent/DE50010833D1/de
Priority to TW089109605A priority patent/TWI241910B/zh
Priority to ARP000102385A priority patent/AR024013A1/es
Publication of DE19923551A1 publication Critical patent/DE19923551A1/de
Priority to IL146277A priority patent/IL146277A/en
Priority to ZA200109517A priority patent/ZA200109517B/en
Priority to US10/942,297 priority patent/US20050053647A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE19923551A 1999-05-21 1999-05-21 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht Withdrawn DE19923551A1 (de)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DE19923551A DE19923551A1 (de) 1999-05-21 1999-05-21 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
PT00929536T PT1183029E (pt) 1999-05-21 2000-05-17 Preparado farmaceutico contendo contendo o principio activo diamorfina e sua utilizacao num processo para o tratamento da dependencia de opiaceos
MXPA01011921A MXPA01011921A (es) 1999-05-21 2000-05-17 Preparacion farmaceutica con diamorfina como sustancia activa y su utilizacion en un procedimiento para el tratamiento de la adicion a los opiaceos.
PCT/EP2000/004458 WO2000071125A2 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat mit dem wirkstoff diamorphin und seine verwendung in einem verfahren zur behandlung der opiatsucht
DK00929536T DK1183029T3 (da) 1999-05-21 2000-05-17 Farmaceutisk præparat indeholdende diamorfin og vitamin E og dets anvendelse til behandling af opiatmisbrug
ES00929536T ES2245311T3 (es) 1999-05-21 2000-05-17 Formulacion farmaceutica que contiene diamorfina y vitamina e, y su utilizacion para el tratamiento de la adiccion a las opiatas.
JP2001505144A JP4892148B2 (ja) 1999-05-21 2000-05-17 活性物質ジアモルフィンからなる医薬生成物およびオピエート嗜癖の処置方法におけるその使用
CNB008078823A CN100457107C (zh) 1999-05-21 2000-05-17 含有海洛因作为活性物质的药物制剂及其于治疗鸦片成瘾上的用途
PL351681A PL196741B1 (pl) 1999-05-21 2000-05-17 Preparat farmaceutyczny, sposób jego wytwarzania i zastosowanie pochodnej (-) morfiny
KR1020017014818A KR100742471B1 (ko) 1999-05-21 2000-05-17 활성 물질 디아모르핀을 포함하는 약학 제제 및 아편제중독증의 치료 방법에서의 그의 용도
EP00929536A EP1183029B1 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
CZ20014187A CZ301230B6 (cs) 1999-05-21 2000-05-17 Farmaceutický prípravek pro kontinuální a rízené podávání, transdermální terapeutický systém, zpusob jejich výroby a jejich použití pro výrobu léciv pro ošetrení závislosti na opiátech
AT00929536T ATE300301T1 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
RU2001134016/15A RU2254130C2 (ru) 1999-05-21 2000-05-17 Фармацевтический препарат с биологически активным веществом диаморфином и его применение в способе лечения опиатомании
BR0011286-0A BR0011286A (pt) 1999-05-21 2000-05-17 Preparado farmacêutico com a substância ativa diamorfina e seu emprego em um processo para tratamento de vìcio em ópio
TR2001/03302T TR200103302T2 (tr) 1999-05-21 2000-05-17 Diamorfin etkin maddeli farmasötik preparat
HU0201349A HUP0201349A3 (en) 1999-05-21 2000-05-17 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a treating opiate addiction
AU47577/00A AU772139B2 (en) 1999-05-21 2000-05-17 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction
IL14627700A IL146277A0 (en) 1999-05-21 2000-05-17 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
NZ515301A NZ515301A (en) 1999-05-21 2000-05-17 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
CA002372339A CA2372339C (en) 1999-05-21 2000-05-17 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
DE50010833T DE50010833D1 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
TW089109605A TWI241910B (en) 1999-05-21 2000-05-18 Pharmaceutical composition for transdermal absorption for treating opiate addiction comprising diamorphine
ARP000102385A AR024013A1 (es) 1999-05-21 2000-05-19 Preparado farmaceutico con diamorfina como sustancia activa, y su utilizacion en un procedimiento para el tratamiento de la adiccion a los opiaceos
IL146277A IL146277A (en) 1999-05-21 2001-11-01 A medical product containing the active substance diamorphine and its use in the process of treating opiate addiction
ZA200109517A ZA200109517B (en) 1999-05-21 2001-11-19 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction.
US10/942,297 US20050053647A1 (en) 1999-05-21 2004-09-16 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19923551A DE19923551A1 (de) 1999-05-21 1999-05-21 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht

Publications (1)

Publication Number Publication Date
DE19923551A1 true DE19923551A1 (de) 2000-11-30

Family

ID=7908879

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19923551A Withdrawn DE19923551A1 (de) 1999-05-21 1999-05-21 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
DE50010833T Expired - Lifetime DE50010833D1 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50010833T Expired - Lifetime DE50010833D1 (de) 1999-05-21 2000-05-17 Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht

Country Status (25)

Country Link
US (1) US20050053647A1 (zh)
EP (1) EP1183029B1 (zh)
JP (1) JP4892148B2 (zh)
KR (1) KR100742471B1 (zh)
CN (1) CN100457107C (zh)
AR (1) AR024013A1 (zh)
AT (1) ATE300301T1 (zh)
AU (1) AU772139B2 (zh)
BR (1) BR0011286A (zh)
CA (1) CA2372339C (zh)
CZ (1) CZ301230B6 (zh)
DE (2) DE19923551A1 (zh)
DK (1) DK1183029T3 (zh)
ES (1) ES2245311T3 (zh)
HU (1) HUP0201349A3 (zh)
IL (2) IL146277A0 (zh)
MX (1) MXPA01011921A (zh)
NZ (1) NZ515301A (zh)
PL (1) PL196741B1 (zh)
PT (1) PT1183029E (zh)
RU (1) RU2254130C2 (zh)
TR (1) TR200103302T2 (zh)
TW (1) TWI241910B (zh)
WO (1) WO2000071125A2 (zh)
ZA (1) ZA200109517B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047556A1 (de) * 2001-12-05 2003-06-12 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit verbessertem langzeittragekomfort
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1418862A2 (en) * 2001-06-29 2004-05-19 Leon J. Lewandowski Individualized addiction cessation therapy

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
DE60112769T2 (de) * 2000-09-08 2006-06-08 San-Ei Gen F.F.I., Inc., Toyonaka Tetraphenylbacteriochlorinderivate und diese enthaltdenden Zusammensetzungen
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
MX366832B (es) * 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070202185A1 (en) * 2005-12-28 2007-08-30 Kimberly-Clark Worldwide, Inc. Microencapsulated Delivery Vehicles Having Fugitive Layers
US7914891B2 (en) * 2005-12-28 2011-03-29 Kimberly-Clark Worldwide, Inc. Wipes including microencapsulated delivery vehicles and phase change materials
US20070149435A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Cleansing composition including microencapsulated delivery vehicles
US20070148446A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Wipes including microencapsulated delivery vehicles and processes of producing the same
US7442439B2 (en) * 2005-12-28 2008-10-28 Kimberly-Clark Worldwide, Inc. Microencapsulated heat delivery vehicles
US20070148448A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Microencapsulated delivery vehicles including cooling agents
US20070148459A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Microencapsulated delivery vehicles
US20070145619A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Processes for producing microencapsulated delivery vehicles
US20070145618A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Methods of making microencapsulated delivery vehicles
US7654412B2 (en) * 2006-05-30 2010-02-02 Kimberly-Clark Worldwide, Inc. Wet wipe dispensing system for dispensing warm wet wipes
US7648046B2 (en) * 2006-05-30 2010-01-19 Kimberly-Clark Worldwide, Inc. Dispensing system for dispensing warm wet wipes
US7497351B2 (en) 2006-05-30 2009-03-03 Kimberly-Clark Worldwide, Inc. Wet wipe dispensing system
EP1889608B1 (en) * 2006-08-09 2012-11-28 Korea Atomic Energy Research Institute Therapeutic hydrogel for atopic dermatitis and preparation method thereof
US8192841B2 (en) * 2006-12-14 2012-06-05 Kimberly-Clark Worldwide, Inc. Microencapsulated delivery vehicle having an aqueous core
WO2008136699A1 (fr) * 2007-05-04 2008-11-13 Igor Alexandrovich Bazikov Patch transdermique à microcapsules et procédé de fabrication correspondant
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US7924142B2 (en) * 2008-06-30 2011-04-12 Kimberly-Clark Worldwide, Inc. Patterned self-warming wipe substrates
EP2531047A4 (en) 2010-02-05 2014-03-19 Phosphagenics Ltd CARRIER WITH AN UNINUTRALIZED TOCOPHERYL PHOSPHATE
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
AU2012386221A1 (en) 2012-07-26 2015-02-26 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
WO2018112512A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Process

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3902013A1 (de) * 1989-01-25 1990-09-20 Knoll Ag Pflaster zur transdermalen anwendung
DE3939376C1 (zh) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
DE19654468C1 (de) * 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
WO1992013540A1 (fr) * 1991-02-06 1992-08-20 Guy Parent Onguent antalgique
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
JPH0733681A (ja) * 1993-05-18 1995-02-03 Sekisui Chem Co Ltd 経皮吸収貼付剤
EP0654263B1 (en) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
EP0672416A1 (en) * 1994-03-14 1995-09-20 Euro-Celtique S.A. Pharmaceutical composition comprising diamorphine
JPH08143458A (ja) * 1994-11-17 1996-06-04 Sekisui Chem Co Ltd 経皮吸収貼付剤
GB9605867D0 (en) * 1996-03-20 1996-05-22 Svedman Paul Transdermal device
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3902013A1 (de) * 1989-01-25 1990-09-20 Knoll Ag Pflaster zur transdermalen anwendung
DE3939376C1 (zh) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
DE19654468C1 (de) * 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418862A2 (en) * 2001-06-29 2004-05-19 Leon J. Lewandowski Individualized addiction cessation therapy
EP1418862A4 (en) * 2001-06-29 2010-06-09 Leon J Lewandowski INDIVIDUALIZED SEARCH THERAPY
WO2003047556A1 (de) * 2001-12-05 2003-06-12 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit verbessertem langzeittragekomfort
US7824707B2 (en) 2001-12-05 2010-11-02 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system provided with improved long-term carrying comfort
US8628795B2 (en) 2001-12-05 2014-01-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic buprenorphine system
US8883198B2 (en) 2001-12-05 2014-11-11 Lts Lohmann Therapie Systeme Ag Transdermal rivastigmine therapeutic system
US9101605B2 (en) 2001-12-05 2015-08-11 Lts Lohmann Therapie Systeme Ag Buprenorphine transdermal therapeutic system and method of administering
US9616045B2 (en) 2001-12-05 2017-04-11 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system having improved long-term wearing comfort
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen

Also Published As

Publication number Publication date
US20050053647A1 (en) 2005-03-10
JP2003502436A (ja) 2003-01-21
CN1362878A (zh) 2002-08-07
CZ20014187A3 (cs) 2002-03-13
KR20020000811A (ko) 2002-01-05
PL351681A1 (en) 2003-06-02
MXPA01011921A (es) 2002-05-06
EP1183029A2 (de) 2002-03-06
WO2000071125A3 (de) 2001-03-15
CZ301230B6 (cs) 2009-12-16
PT1183029E (pt) 2005-09-30
NZ515301A (en) 2004-01-30
ATE300301T1 (de) 2005-08-15
IL146277A (en) 2006-12-10
HUP0201349A3 (en) 2004-12-28
BR0011286A (pt) 2002-03-19
TR200103302T2 (tr) 2002-04-22
CA2372339C (en) 2008-12-23
AR024013A1 (es) 2002-09-04
PL196741B1 (pl) 2008-01-31
DK1183029T3 (da) 2005-11-14
AU4757700A (en) 2000-12-12
IL146277A0 (en) 2002-07-25
CN100457107C (zh) 2009-02-04
RU2254130C2 (ru) 2005-06-20
JP4892148B2 (ja) 2012-03-07
TWI241910B (en) 2005-10-21
WO2000071125A2 (de) 2000-11-30
ZA200109517B (en) 2002-09-26
ES2245311T3 (es) 2006-01-01
HUP0201349A2 (en) 2002-08-28
AU772139B2 (en) 2004-04-08
CA2372339A1 (en) 2000-11-30
DE50010833D1 (de) 2005-09-01
EP1183029B1 (de) 2005-07-27
KR100742471B1 (ko) 2007-07-25

Similar Documents

Publication Publication Date Title
EP1183029B1 (de) Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
DE69020458T2 (de) Transdermale in zwei Phasen wirkende Ausgabevorrichtung für Medikamente.
DE69916492T3 (de) Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
EP0680325A1 (de) Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
EP2582364A2 (de) Transdermale verabreichung von memantin
EP0949925A2 (de) Flache arzneizubereitung zur applikation und freisetzung von buprenorphin oder einer pharmakologisch vergleichbaren substanz in der mundhöhle und verfahren zu ihrer herstellung
EP0430019A2 (de) Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil
DE602004009449T2 (de) Behandlung von entzug
EP1850836B1 (de) Medikamentöse kombinationsbehandlung
EP1143938A2 (de) Transdermales therapeutisches system mit einer selbstklebenden matrix, enthaltend organische säure-additionssalze von alkaloiden des morphin- bzw. morphinantyps
DE10004790B4 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
DE10338544B4 (de) Buccale Formulierungen des Galanthamins und deren Anwendungen
EP1404341B1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
EP0659079B1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
WO2008043601A2 (de) Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil
DE10301930A1 (de) Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8130 Withdrawal